Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.56), $0.25 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $78.5 million versus the consensus estimate of $79.26 million.

“We are pleased to report another positive quarter, delivering strong EXONDYS 51 sales and tracking to achieve our full-year sales objectives while both advancing our RNA pipeline and making substantial progress in the creation of an enduring gene therapy engine,” stated Doug Ingram, Sarepta’s president and chief executive officer. “We continued this quarter to advance our RNA pipeline, PMOs and next-generation PPMO platform, with urgency. Further, the strides we have taken in service of our gene therapy engine, including unprecedented results in our micro-dystrophin program, rights to what are now 14 gene therapy programs, the addition of manufacturing partners, and the continued hiring of gene therapy talent, speak to our vision. Others may be content with steady progress. We see a revolution and it is our intention to lead that revolution to the benefit of countless genetic disease patients awaiting life-enhancing therapies.”

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.